Skip to main content

BAXTER INTERNATIONAL INC

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

BAX$25.79+0.5%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Equity

Condensed Consolidated Statements of Changes in Equity (unaudited)

For the three months ended September 30, 2025
Baxter International Inc. stockholders' equity
Common stock sharesCommon stockCommon stock sharesin treasuryCommon stock intreasuryAdditional contributed capitalRetained earningsAccumulated other comprehensiveincome (loss)Total Baxter stockholders' equityNoncontrolling interestsTotal equity
Balance as of July 1, 2025683$683170$(10,915)$6,328$14,970$(3,746)$7,320$(27)$7,293
Net income (loss)—————(46)—(46)—(46)
Other comprehensive income (loss)——————1313—13
Stock issued under employee benefit plans and other———2417——41—41
Dividends declared on common stock—————(87)—(87)—(87)
Balance as of September 30, 2025683$683170$(10,891)$6,345$14,837$(3,733)$7,241$(27)$7,214
For the nine months ended September 30, 2025
Baxter International Inc. stockholders' equity
Common stock sharesCommon stockCommon stock shares in treasuryCommon stock in treasuryAdditional contributed capitalRetained earningsAccumulated other comprehensive income (loss)Total Baxter stockholders' equityNoncontrolling interestsTotal equity
Balance as of January 1, 2025683$683173$(11,059)$6,421$14,929$(4,010)$6,964$60$7,024
Net income (loss)—————171—171—171
Other comprehensive income (loss)——————162162—162
Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation——————115115—115
Stock issued under employee benefit plans and other——(3)168(76)——92—92
Dividends declared on common stock—————(263)—(263)—(263)
Disposition of noncontrolling interest associated with the Kidney Care separation————————(87)(87)
Balance as of September 30, 2025683$683170$(10,891)$6,345$14,837$(3,733)$7,241$(27)$7,214
For the three months ended September 30, 2024
Baxter International Inc. stockholders' equity
Common stock sharesCommon stockCommon stock shares in treasuryCommon stock in treasuryAdditional contributed capitalRetained earningsAccumulated other comprehensive income (loss)Total Baxter stockholders' equityNoncontrolling interestsTotal equity
Balance as of July 1, 2024683$683173$(11,104)$6,353$15,539$(3,828)$7,643$65$7,708
Net income (loss)—————140—1404144
Other comprehensive income (loss)——————181181—181
Stock issued under employee benefit plans and other———2038——58—58
Dividends declared on common stock—————(150)—(150)—(150)
Change in noncontrolling interests————————11
Balance as of September 30, 2024683$683173$(11,084)$6,391$15,529$(3,647)$7,872$70$7,942
For the nine months ended September 30, 2024
Baxter International Inc. stockholders' equity
Common stock sharesCommon stockCommon stock shares in treasuryCommon stock in treasuryAdditional contributed capitalRetained earningsAccumulated other comprehensive income (loss)Total Baxter stockholders' equityNoncontrolling interestsTotal equity
Balance as of January 1, 2024683$683176$(11,230)$6,389$16,114$(3,554)$8,402$66$8,468
Net income (loss)—————(137)—(137)9(128)
Other comprehensive income (loss)——————(93)(93)(4)(97)
Stock issued under employee benefit plans and other——(3)1462——148—148
Dividends declared on common stock—————(448)—(448)—(448)
Change in noncontrolling interests————————(1)(1)
Balance as of September 30, 2024683$683173$(11,084)$6,391$15,529$(3,647)$7,872$70$7,942
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.